22nd Century Group to Announce Fourth Quarter and Full Year 2021 Results on March 1, 2022
February 03, 2022 09:20 ET
|
22nd Century Group, Inc
BUFFALO, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco,...
22nd Century Group VP of Regulatory Science to Participate in FDLI Panel in Response to Recent FDA Action on Comprehensive Plan and Reduced Nicotine Mandate
October 13, 2021 16:01 ET
|
22nd Century Group, Inc
Company Supports This Week’s Positive FDA Action on E-Cigarettes, Demonstrating the Agency’s Commitment to Providing Adult Smokers with Alternatives to Highly Addictive CigarettesApplauds FDA’s Active...
22nd Century to Present at SNN Network Investor Conference on August 19
August 17, 2021 09:20 ET
|
22nd Century Group, Inc
BUFFALO, N.Y., Aug. 17, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and...
22nd Century Group Reports Business Highlights and Financial Results for the Second Quarter 2021
August 05, 2021 06:00 ET
|
22nd Century Group, Inc
Initiated International Launch Process For VLN®, First Sales Planned by First Quarter 2022First Revenue From Hemp/Cannabis Franchise to Commence in Second Half of 2021Third Plant-Based Franchise to be...
22nd Century Appoints Leading Plant Biotechnology Expert Dr. Michael Koganov to Board of Directors
September 17, 2020 16:05 ET
|
22nd Century Group, Inc
WILLIAMSVILLE, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant-based, life science company driven by next...
22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer
June 03, 2020 06:45 ET
|
22nd Century Group, Inc
Mish brings extensive global executive leadership experience in the development, manufacturing and commercialization of active pharmaceutical ingredients, including cannabinoids, and related consumer...